

**ATRIPLA®**  
**Country-by-Country Registration Status\***  
**October 2009**

Approved	Filed	Available
1. Botswana	1. Angola ^	1. Antigua and Barbuda
2. Bolivia	2. Benin	2. Bahamas
3. Burkina Faso	3. Cape Verde	3. Barbados
4. Burundi	4. Djibouti	4. Belize
5. Cameroon	5. Dominican Republic	5. Cambodia
6. Central African Republic	6. Ghana	6. Dominica
7. Chad	7. Guinea – Bissau ^	7. Grenada
8. Congo-Brazzaville	8. Madagascar	8. Guyana
9. Congo-Kinshasa	9. Maldives	9. Haiti
10. Cote d'Ivoire	10. Mali	10. Kiribati
11. Equatorial Guinea	11. Mauritius	11. Lao Republic
12. Ethiopia	12. Namibia	12. Mongolia
13. Gabon	13. Niger	13. Nepal
14. Gambia	14. Rwanda	14. Papua New Guinea
15. Guinea	15. South Africa	15. Saint Kitts and Nevis
16. Guatemala	16. Syria	16. Saint Lucia
17. Honduras	17. Trinidad & Tobago	17. Saint Vincent and Grenadines
18. Jamaica	18. Ukraine	18. Samoa
19. Kenya		19. Solomon Islands
20. Mauritania		20. Suriname
21. Mozambique		21. Timor-Leste
22. Nicaragua		22. Tuvalu
23. Nigeria		23. Vanuatu
24. Panama		24. Yemen
25. Senegal		
26. Tanzania		
27. Togo		
28. Uganda		
29. Zambia		

**ATRIPLA®**  
**Country-by-Country Registration Status\***  
**October 2009**

Disclaimer: There can be no guarantee that marketing approval for ATRIPLA® will be granted in any of the countries where registration is pending, and any marketing approval, if granted, may have significant limitations on its use.

Terms and Definitions

Approved: Countries where the dossier has been submitted and approved

Filed: Countries where the dossier has been submitted and review is pending

Available: Countries where Merck makes ATRIPLA® available through locally acceptable alternative mechanisms

\*: ATRIPLA® is a trademark of Bristol-Myers Squibb and Gilead Sciences, LLC. ATRIPLA® is marketed by Bristol-Myers Squibb and Gilead in the United States, Canada, the European Union, Norway and Iceland

^: Countries where Merck makes ATRIPLA® available prior to marketing approval through locally acceptable mechanisms